Genentech Chooses to Blind People for Profit

Here is what is going on, Genentech makes two drugs, Avastin and Lucentis. The former is used to treat colon cancer, and the latter "wet" macular degeneration, one of the more common forms of blindness.

The drugs are very similar, but Avastin, when cut to a dosage for eye treatment, costs about $38.00/dose, as opposed to Lucentis, which wholesales for $1,950.00 a dose (no, I have not misplaced a decimal place.

So now Genentech is going to cut off pharmacists it believes are delivering the drug to ophthalmologists who use it in an off label application.

They claim that it's safety concerns. Bullsh$#!